Literature DB >> 1383389

Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens.

D J Rawlings1, D C Kaslow.   

Abstract

Immune responses in major histocompatibility complex (MHC)-disparate congenic mouse strains immunized with sexual stage malaria parasites or purified recombinant protein were adjuvant dependent. Whereas mice exhibited a limited antibody response to immunization with newly emerged Plasmodium falciparum gametes in Freund's adjuvant, all five congenic mouse strains responded to several transmission-blocking vaccine candidate antigens, when parasites were emulsified in a monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) adjuvant. The humoral response in those animals immunized with the antigen in a MPL/TDM adjuvant was helper T cell dependent, as evident by boosting of the antibody response after a second immunization. If the immunogen consisted of purified recombinant protein, then the immune response was not MHC class II limited in mice immunized with either complete Freund's adjuvant or TDM/MPL. The potential role of adjuvants in overcoming apparent immune nonresponsiveness and the implications for development of a malaria transmission-blocking vaccine are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383389      PMCID: PMC2119424          DOI: 10.1084/jem.176.5.1483

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

1.  Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; S P Chang; H Gibson; A Hashimoto; C Hashiro; P J Barr; S Kotani
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

2.  Limited immunological recognition of critical malaria vaccine candidate antigens.

Authors:  M F Good; L H Miller; S Kumar; I A Quakyi; D Keister; J H Adams; B Moss; J A Berzofsky; R Carter
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

3.  Plasmodium gallinaceum: exflagellation stimulated by a mosquito factor.

Authors:  M M Nijhout
Journal:  Exp Parasitol       Date:  1979-08       Impact factor: 2.011

4.  Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide.

Authors:  P J Baker; M B Fauntleroy; P W Stashak; J R Hiernaux; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

5.  Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2.

Authors:  M F Good; D Pombo; M N Lunde; W L Maloy; R Halenbeck; K Koths; L H Miller; J A Berzofsky
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

6.  Complete in vitro maturation of Plasmodium falciparum gametocytes.

Authors:  T Ifediba; J P Vanderberg
Journal:  Nature       Date:  1981-11-26       Impact factor: 49.962

7.  Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.

Authors:  I A Quakyi; L N Otoo; D Pombo; L Y Sugars; A Menon; A S De Groot; A Johnson; D Alling; L H Miller; M F Good
Journal:  Am J Trop Med Hyg       Date:  1989-08       Impact factor: 2.345

8.  T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine.

Authors:  L Kabilan; M Troye-Blomberg; H Perlmann; G Andersson; B Högh; E Petersen; A Björkman; P Perlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Association between HLA type and antibody response to malaria sporozoite and gametocyte epitopes is not evident in immune Papua New Guineans.

Authors:  P M Graves; K Bhatia; T R Burkot; M Prasad; R A Wirtz; P Beckers
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

10.  Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine.

Authors:  M F Good; J A Berzofsky; W L Maloy; Y Hayashi; N Fujii; W T Hockmeyer; L H Miller
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more
  13 in total

1.  Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.

Authors:  C A Lobo; R Dhar; N Kumar
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.

Authors:  A W Stowers; D B Keister; O Muratova; D C Kaslow
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

Review 4.  Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.

Authors:  Ajay K Saxena; Yimin Wu; David N Garboczi
Journal:  Eukaryot Cell       Date:  2007-06-08

5.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

6.  Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.

Authors:  George Hui; Dan Choe; Caryn Hashimoto
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

7.  STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity.

Authors:  Sanjay Varikuti; Steve Oghumu; Gayathri Natarajan; Jennifer Kimble; Rachel H Sperling; Ellen Moretti; Mark H Kaplan; Abhay R Satoskar
Journal:  Int Immunol       Date:  2016-08-30       Impact factor: 4.823

8.  Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages.

Authors:  I P Oswald; C M Dozois; J F Petit; G Lemaire
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

9.  Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1.

Authors:  G S Hui; C N Hashimoto
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Authors:  Delia F Tifrea; Sukumar Pal; Christel le Bon; Melanie J Cocco; Manuela Zoonens; Luis M de la Maza
Journal:  Vaccine       Date:  2020-04-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.